Tenofovir Disoproxil Fumarate in HIV-Infected Patients Who Have Not Had Success With Other Anti-HIV Drug Combinations

Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults

NCT01967940 ·Status: COMPLETED ·Phase: PHASE3

Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF

NCT02121795 ·Status: COMPLETED ·Phase: PHASE3

Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

NCT01533259 ·Status: COMPLETED ·Phase: PHASE3

Study of Tenofovir Disoproxil Fumarate (TDF) for Prevention of HIV

NCT00122486 ·Status: COMPLETED ·Phase: PHASE2

Effect of Tenofovir Disoproxil Fumarate on Lipid Levels in HIV Infected Adults on Stable Anti-HIV Drug Therapy

NCT00109603 ·Status: COMPLETED ·Phase: NA

D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults

NCT01565850 ·Status: COMPLETED ·Phase: PHASE2

Metabolic Impact Assessment of Tenofovir Disoproxil Fumarate on Non-HIV-1 Infected Healthy Adult Male Volunteers

NCT00648817 ·Status: COMPLETED ·Phase: PHASE4

A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Receiving Care in a Test and Treat Model of Care

NCT03227861 ·Status: COMPLETED ·Phase: PHASE3

Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults

NCT01968551 ·Status: COMPLETED ·Phase: PHASE3

A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients

NCT00089492 ·Status: COMPLETED ·Phase: PHASE2

Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I

NCT02616029 ·Status: COMPLETED ·Phase: PHASE3

Study to Evaluate Switching From a Regimen Consisting of the Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (STR) to the Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate STR

NCT01286740 ·Status: COMPLETED ·Phase: PHASE2

Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF

NCT01252940 ·Status: COMPLETED ·Phase: PHASE3

Effect of Tenofovir DF on Bone Metabolism in Children

NCT00088309 ·Status: COMPLETED ·Phase: PHASE2

Treatment Intensification for HIV Infected Patients With Multi-Drug Resistant Virus

NCT00102934 ·Status: UNKNOWN ·Phase: NA

Evaluating the Effect of CHanging EnfuvirtidE to Raltegravir in HIV Infected Subjects

NCT00529243 ·Status: COMPLETED ·Phase: PHASE3

Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants

NCT02269917 ·Status: COMPLETED ·Phase: PHASE3

Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)

NCT06101329 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Examining Hair to Determine Tenofovir Exposure

NCT00903084 ·Status: COMPLETED ·Phase: PHASE1

Evaluation of the Cellular Pharmacology of Tenofovir and Emtricitabine According to HIV Infection Status

NCT01040091 ·Status: COMPLETED ·Phase: PHASE1

The Benefits of Immediate Treatment Initiation Without Immunovirological Data Compared to Conventional BIC / FTC / TAF Treatment in Naive Patients With Type 1 HIV (Human Immunodeficiency Virus) Infection

NCT05606055 ·Status: COMPLETED ·Phase: PHASE4

A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1

NCT00100984 ·Status: TERMINATED ·Phase: PHASE4

Single Tablet Regimen (STR) Simplification Study for HIV-1 Infected Patients

NCT00365612 ·Status: COMPLETED ·Phase: PHASE4

Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants

NCT03631732 ·Status: COMPLETED ·Phase: PHASE3

Study of Enfuvirtide in HIV-Positive Subjects

NCT00086710 ·Status: COMPLETED ·Phase: PHASE1